high cholesterol
NICE recommends Sanofi, Amgen cholesterol drugs
May 6, 2016Medical Communications, Sales and Marketing Amgen, Draft Guidance, NHS, NICE, Repatha, Sanofi, cardiovascular disease, cholesterol, final draft guidance, high cholesterol, praluent, recommendation, treatment
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …
Amgen earns first Japanese nod for PCSK9 inhibitor
January 25, 2016Sales and Marketing Amgen, Astellas, Japan, PCSK9 inhibitor, Repatha, evolocumab, high cholesterol
The Japanese Ministry of Health, Labour and Welfare has approved Amgen’s cholesterol-lowering medication Repatha, in a joint venture between Amgen …
NICE rejects Amgen’s Repatha in draft guidance
November 18, 2015Research and Development, Sales and Marketing Amgen, NICE, Repatha, evolocumab, high cholesterol
NICE has published draft guidance rejecting Amgen’s Repatha as a treatment for people with high cholesterol.
NICE issues draft guidance for MSD’s Ezetrol
October 21, 2015Sales and Marketing MSD, NICE, cardiovascular disease, ezetimibie, ezetrol, high cholesterol
NICE has published draft guidance recommending MSD’s Ezetrol as an option for some adults with high cholesterol. The guidance updates …
Sanofi and Regeneron heart drug Praluent available in UK
October 19, 2015Sales and Marketing Regeneron, Sanofi, alicrocumab, high cholesterol, praluent
Sanofi and Regeneron’s next-generation cholesterol-lowering treatment Praluent is now available for adult patients with high cholesterol in the UK, following …
Lilly shares fall as company abandons evacetrapib development
October 13, 2015Manufacturing and Production evacetrapib, high cholesterol, lilly, phase III, phase III failure
Eli Lilly shares fell by nearly 8% this week as the company announced it will abandon developmenty of the investigational …
Sanofi and Regeneron given European nod for Praluent
September 28, 2015Sales and Marketing European Commission, Regeneron, Sanofi, alirocumab, high cholesterol, marketing authorisation, praluent
The European Commission (EC) has approved the marketing authorisation of Sanofi and Regeneron’s cholesterol drug Praluent. The heart drug is …
Amgen joins M&A rush with deals for Dezima and Xencor
September 16, 2015Research and Development, Sales and Marketing Amgen, Cancer, Denzime, Xencor, cardiovascular disease, high cholesterol, inflammation
Amgen has struck deals that could potentially be worth $3.25 billion, to purchase the Dutch firm Dezima and kick-off a …
NHS looks to ESC for next-gen heart drug data
August 28, 2015Medical Communications, Research and Development ALN-PCScs, Repatha, alirocumab, cardiology, cardiovascular disease, cvd, evolocumab, heart disease, high cholesterol, praluent
New data is expected to be presented at the European Cardiology Society congress in London, on the high cholesterol drugs …
FDA and EMA approve heart drug Praluent
July 27, 2015Sales and Marketing EMA, FDA, PCSK9, Regeneron, Sanofi, high cholesterol, praluent
The FDA and the EMA have both approved Sanofi and Regeneron’s new high cholesterol drug Praluent. Regulators on both sides …
Amgen’s Repatha wins PCSK9 heart drug race
July 21, 2015Sales and Marketing Amgen, European Commission, PCKS9, Repatha, evolocumab, high cholesterol
The European Commission has signed off on Amgen’s Repatha, making it the first in a new class of cholesterol-lowering drugs …
Praluent scores positive trial results in Japan
July 9, 2015Research and Development Japan, PCKS9, Regeneron, Sanofi, heart disease, high cholesterol, praluent
Praluent, the new heart drug from Sanofi and Regeneron, has met its primary endpoint in a Phase III study in …
Amarin expands US operations
February 10, 2011Sales and Marketing AMR101, Amarin, Paul Huff, high cholesterol
Dublin-based biopharmaceutical company Amarin is to increase its US presence by setting up sales and marketing headquarters in New Jersey. …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
